| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 7, 2025 | Avacta Announces Agreement to Sell Launch Diagnostics and a Corporate Update | LONDON AND PHILADELPHIA, March 07, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘the Company’), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to ... |
| Jan 16, 2025 | Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers | Meaningful tumor shrinkage observed in five out of 10 patients with partial and minor responses and 90% disease control rate in patients with salivary gland cancers
Phase 1b expansion cohorts screening patients in triple negative breast can... |
| Jan 6, 2025 | Зарубежные IPO 2024 года: какие компании стали публичными | В 2024 году на фондовом рынке США 193 компании провели первичное размещение своих акций. К 20 ноября объем IPO вырос на 34,03% по сравнению с аналогичным периодом 2023 года. 75% компаний, вышедших на биржу к июлю 2024 года, принесли акционе... |
| Oct 10, 2024 | Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium | 10 October
Avacta Group plc
(“Avacta” or “the Group” or “the Company”)
Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium
LONDON, UK, 10 OCT 2024, Avacta Group ... |
| Sep 14, 2024 | Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors | This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon t... |
| Apr 5, 2024 | Avacta Group - AVA6000 Abstract Release by AACR and Full Presentation Update | 5 April 2024
Avacta Group plc
(“Avacta” or “the Group” or “the Company”)
AVA6000 Abstract Release by AACR and Full Presentation Update
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and ... |
| Jan 18, 2022 | Avacta : Selects Second pre|CISIONTM Pro-drug Candidate for Development | Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces that the next pre|CISIONTM drug c... |
| Jan 18, 2022 | Avacta selects second pre|CISION™ pro-drug candidate for development | Avacta selects second pre|CISION™ pro-drug candidate for development
18-01-2022
Cambridge and Wetherby, UK: Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnos... |
| Dec 22, 2021 | Avacta : AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing | Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces that the AffiDX® SARS-CoV-2 anti... |
| Dec 22, 2021 | Avacta announces AffiDX® SARS-CoV-2 antigen lateral flow test receives CE mark for consumer self-testing | Avacta announces AffiDX® SARS-CoV-2 antigen lateral flow test receives CE mark for consumer self-testing
22-12-2021
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful... |
| Dec 16, 2021 | Avacta announces AffiDx SARS-CoV-2 antigen lateral flow test detects the Omicron variant | Avacta announces AffiDx SARS-CoV-2 antigen lateral flow test detects the Omicron variant
16-12-2021
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics bas... |
| Sep 30, 2021 | Avacta : Interim Results for the Period Ended 30 June 2021 and Business Update | Transformative period for both Diagnostics and Therapeutics Divisions
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer®... |
| Sep 29, 2021 | Avacta announces achievement of pre-clinical development milestone in LG Chem Life Sciences partnership | Avacta announces achievement of pre-clinical development milestone in LG Chem Life Sciences partnership
29-09-2021
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful ... |
| Sep 6, 2021 | Avacta : announces new appointments to the Scientific Advisory Board of its Therapeutics Division | Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces new appointments to its Scientif... |
| Sep 2, 2021 | Avacta : Appointment of Dr Fiona McLaughlin as Chief Scientific Officer of Avacta's Therapeutics Division | Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces the appointment of Dr Fiona McLa... |
| Aug 18, 2021 | Avacta : Directorate Change | Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces the appointment of Dr Mark Goldberg as Non-executive Director t... |
| Aug 11, 2021 | Avacta announces first patient dosed in AVA6000 Pro-Doxorubicin Phase I clinical trial | Avacta announces first patient dosed in AVA6000 Pro-Doxorubicin Phase I clinical trial
11-08-2021
Cambridge and Wetherby... Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and ... |
| Jun 21, 2021 | Avacta announces AffiDX® SARS-CoV-2 antigen lateral flow test distribution agreement | Avacta announces AffiDX® SARS-CoV-2 antigen lateral flow test distribution agreement
21-06-2021
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ pla... |
| Jun 7, 2021 | MHRA confirms registration of Avacta’s AffiDX SARS-CoV-2 antigen lateral flow test | MHRA confirms registration of Avacta’s AffiDX SARS-CoV-2 antigen lateral flow test
07-06-2021
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platf... |
| May 25, 2021 | AVACTA GROUP PLC
Avacta : Posting of Annual Report and Notice of AGM | Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that its Annual Report and Accounts for the year ended 31 Decembe... |
| May 10, 2021 | Avacta : AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Update | Submission of Declaration of Conformity for CE mark for Avacta's rapid antigen test
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is p... |
| Apr 22, 2021 | AVACTA GROUP PLC
Avacta : Preliminary Results for the year ending 31 December 2020 | Significant progress in Diagnostics and Therapeutics Divisions
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce it... |
| Apr 20, 2021 | Avacta : Clinical validation of AffiDX® SARS-CoV-2 Antigen Lateral Flow Test | 98.0% clinical sensitivity for samples with PCR Ct values1 up to 31
Completing the technical data set for self-declaration of a CE mark for professional use in early May, followed immediately by commercial launch in Europe
Avacta Group plc ... |
| Apr 20, 2021 | Avacta receives clinical validation of AffiDX SARS-CoV-2 antigen lateral flow test | Avacta receives clinical validation of AffiDX SARS-CoV-2 antigen lateral flow test
20-04-2021
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platf... |
| Apr 6, 2021 | Avacta announces distribution agreement with Abcam plc | Avacta announces distribution agreement with Abcam plc
06-04-2021
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce... |
| Mar 8, 2021 | Avacta’s rapid antigen test is confirmed to detect SARS-CoV-2 new variants | Avacta’s rapid antigen test is confirmed to detect SARS-CoV-2 new variants
08-03-2021
Avacta’s AffiDX SARS-CoV-2 lateral flow test detects both B117 ‘Kent’ and D614G variants of the virus.
Cambridge and Wetherby, UK: Avacta Group plc (AIM: ... |
| Feb 18, 2021 | Avacta announces phase 1 Clinical Trial Authorisation (CTA) for AVA6000 approved by MHRA | Avacta announces phase 1 Clinical Trial Authorisation (CTA) for AVA6000 approved by MHRA
18-02-2021
Cambridge and Wetherby, 18 February 2021: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, announces th... |
| Feb 16, 2021 | Avacta announces results of initial evaluation of SARS-CoV-2 lateral flow antigen test with clinical samples | Avacta announces results of initial evaluation of SARS-CoV-2 lateral flow antigen test with clinical samples
16-02-2021
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, announces that it has received the... |
| Feb 16, 2021 | Avacta : Results of Initial Evaluation of SARS-CoV-2 Lateral Flow Antigen Test with Clinical Samples | Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, announces that it has received the first data for its SARS-CoV-2 rapid antigen test from ongoing clinical studies in Europe and the UK. These data show ex... |
| Feb 9, 2021 | Avacta Group plc announces commercial partnership with Mologic | Avacta Group plc announces commercial partnership with Mologic
09-02-2021
New partnership aims to accelerate CE marking of Avacta’s SARS-CoV-2 rapid antigen test and support COVID-19 testing in low and middle income countries.
Avacta Group ... |
| Feb 2, 2021 | Avacta announces AffyXell $7.3 million Series A financing | Avacta announces AffyXell $7.3 million Series A financing
02-02-2021
Avacta’s next generation cell and gene therapy joint venture with Daewoong Pharmaceutical secures Series A venture funding.
Avacta Group plc (AIM: AVCT), the developer of ... |
| Feb 2, 2021 | Avacta announces AffyXell $7.3 million Series A financing | Avacta’s next generation cell and gene therapy joint venture with Daewoong Pharmaceutical secures Series A venture funding.
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that Af... |
| Feb 1, 2021 | AVACTA GROUP PLC
Avacta : announces AffyXell $7.3 Million Series A Financing | Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that AffyXell Therapeutics (“AffyXell”), the joint venture with Daewoong Pharmaceutical (“Daewoong”), has closed a Series A venture... |
| Feb 1, 2021 | AVACTA GROUP PLC
Avacta : AffyXell $7.3 Million Series A Financing | Avacta's next generation cell and gene therapy joint venture with Daewoong Pharmaceutical secures Series A venture funding
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that Aff... |
| Feb 1, 2021 | Avacta : AffyXell $7.3 Million Series A Financing | Avacta's next generation cell and gene therapy joint venture with Daewoong Pharmaceutical secures Series A venture funding
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that Aff... |
| Feb 1, 2021 | Avacta : announces AffyXell $7.3 Million Series A Financing | Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that AffyXell Therapeutics (“AffyXell”), the joint venture with Daewoong Pharmaceutical (“Daewoong”), has closed a Series A venture... |
| Jan 7, 2021 | Avacta announces licence agreement with POINT Biopharma Inc. | Avacta announces licence agreement with POINT Biopharma Inc.
07-01-2021
Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that ... |
| Dec 23, 2020 | Avacta submits clinical trial application for AVA6000 pro-doxorubixin | Avacta submits clinical trial application for AVA6000 pro-doxorubixin
23-12-2020
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is plea... |
| Oct 1, 2020 | Avacta launches SARS-CoV-2 BAMS Research Test | Avacta launches SARS-CoV-2 BAMS Research Test
01-10-2020
Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the BAMS™ assay... |
| Aug 7, 2020 | Avacta announces SARS-CoV-2 rapid antigen test clinical collaboration | Avacta announces SARS-CoV-2 rapid antigen test clinical collaboration
07-08-2020
Avacta and Liverpool School of Tropical Medicine collaborate to clinically validate saliva-based rapid coronavirus test being developed with Cytiva.
Avacta Gro... |
| Aug 6, 2020 | Avacta appoints COVID-19 rapid antigen test manufacturing partner | Avacta appoints COVID-19 rapid antigen test manufacturing partner
06-08-2020
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has appointed BBI Solutions, part of BBI Group, to manufac... |
| Jul 29, 2020 | Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy | Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy
29-07-2020
Increased collaboration aims to develop stem cell therapies for COVID-19 and future pandemic diseases.
Avacta Group plc (AIM: ... |
| May 15, 2020 | Avacta develops SARS-COV-2 neutralising Affimer reagents with therapeutic potential for COVID-19 | Avacta develops SARS-COV-2 neutralising Affimer reagents with therapeutic potential for COVID-19
15-05-2020
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that several of the Affimer reagent... |
| May 1, 2020 | Avacta Group plc forms COVID-19 antigen diagnostic collaboration with Adeptrix | Avacta Group plc forms COVID-19 antigen diagnostic collaboration with Adeptrix
01-05-2020
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with Adeptri... |
| Mar 12, 2020 | Cofinitive shortlisted in 30th Anniversary Business Weekly Awards | Cofinitive shortlisted in 30th Anniversary Business Weekly Awards
12-03-2020
Cofinitive are delighted to announce that they have been shortlisted in the upcoming Business Weekly Awards.
The shortlist has listed us as “a growing team of comm... |
| Jan 13, 2020 | Avacta and Daewoong Pharmaceutical form joint venture focused on iImmunotherapy | Avacta and Daewoong Pharmaceutical form joint venture focused on iImmunotherapy
13-01-2020
The European Life Sciences team at Goodwin advised Avacta Life Sciences Limited on the completion of its agreement with Daewoong Pharmaceutical Co., ... |
| Oct 10, 2019 | Zantac pulled off shelves due to cancer scare; The end of the road for Motif Bio | → GSK is recalling its heartburn medicine Zantac, sold generically as ranitidine, from all markets after the FDA found it contains “‘unacceptable’ levels of probable cancer-causing impurity.” The drug is one of sev... |
| Feb 27, 2019 | Cofinitive shortlisted for International Trade Champion award at Business Weekly Awards | Cofinitive shortlisted for International Trade Champion award at Business Weekly Awards
27-02-2019
Cofinitive is delighted to announce it has been shortlisted among the brightest and best of elite Cambridge-based companies in the upcoming B... |
| Aug 2, 2016 | Zika protein developed by Mercia ‘Emerging Star’ used to generate unique tools for virus detection | The Native Antigen Company, a former University of Birmingham spinout specialising in the research, development and manufacture of high purity viral and bacterial products, has collaborated with Avacta Group plc to create unique tools to de... |
| Jun 13, 2016 | Avacta and Mologic enter research and product development collaboration agreement | Avacta and Mologic enter research and product development collaboration agreement
13-06-2016
Avacta Group plc, the developer of Affimer® biotherapeutics and research reagents, and Mologic, a specialist diagnostic development company, today ... |
